DermTech, LLC

A new study published in the American Journal of Dermatopathology aimed to independently evaluate the real-world performance of the DermTech Melanoma Test using data from a large group of dermatology practices. https://bit.ly/AJDP_DMT

Wishing you a very Happy Thanksgiving from our team at DermTech, LLC.

New in JAAD: This study assessed the DermTech Melanoma Test across all skin types in a real-world clinical setting and compared the test's performance in patients with Fitzpatrick skin phototypes I-III to its performance in patients with skin phototypes IV-VI. The negative predictive value (NPV) for both groups exceeded 99%. The 95% confidence interval indicated no significant difference in performance metrics – sensitivity, specificity, positive predictive value, or NPV - between the skin phototype groups.

Key study published in JAAD: "Clinical Performance of a Noninvasive Melanoma Rule-Out Test Across Fitzpatrick Skin Types." "This study demonstrated that regardless of a patient's skin type, the DMT can augment the detection of melanoma at an early stage, while reducing the number of biopsies performed for benign lesions that mimic melanoma," said Maral Skelsey, MD, lead author and medical director of the Dermatologic Surgery Center of Washington. "The high NPV indicates that a negative result for a suspicious or equivocal pigmented lesion makes it highly unlikely to be a melanoma."

Thank you Medical Assistants ! DermTech recognizes all of the support Medical Assistants provide to make physician offices run smoothly. We appreciate you!

 "Evaluating moles to appropriately rule out melanoma and guide biopsy decisions remains challenging, even for experienced dermoscopists. Early in situ and even some invasive melanomas can have very few morphologic features. Non-invasive genomic testing provides an additional technology beyond using just what moles look like morphologically to enable better pigmented lesion management for our patients," Gary L. Peck, MD, a recent selection to the American Academy of Dermatology's "Titans of Dermatology" and the study's lead author.

New publication in JDD: "We find genomic testing essential in deciding which atypical moles should be biopsied and which should be monitored. Having used DermTech's melanoma rule-out test on over 5,000 patients, we have seen that NI-GEP technology benefits our patients and our business," Maral Skelsey MD, medical director of the Dermatologic Surgery Center of DC.

DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management

Allyson Perry, PhD is at #SID2024 in Dallas, TX presenting new data on performance of the DermTech Melanoma Test in the pediatric population. The DermTech Pediatric Registry collected data on 1440 clinically equivocal pigmented lesions from 19 dermatology practices across the United States. The test demonstrated a negative predictive value of >99% for ruling out melanoma as well as severely dysplastic nevi. Stop by poster 630 for more information. Society for Investigative Dermatology #precisiongenomics

Happy #LabWeek to all of the hardworking lab professionals! We want to give a special shoutout to our very own members of the DermTech Gene Lab. For all the work you do—this week, and every week—thank you.   #LabWeek2024